ST3Gal3 confers paclitaxel‑mediated chemoresistance in ovarian cancer cells by attenuating caspase‑8/3 signaling

Zhang,Xian; Yang,Xinying; Chen,Ming; Zheng,Shaolie; Li,Jinyuan; Lin,Shaoqiang; Wang,Xiaoyu

doi:10.3892/mmr.2019.10712

ST3Gal3 confers paclitaxel‑mediated chemoresistance in ovarian cancer cells by attenuating caspase‑8/3 signaling

Authors:
- Xian Zhang
- Xinying Yang
- Ming Chen
- Shaolie Zheng
- Jinyuan Li
- Shaoqiang Lin
- Xiaoyu Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510630, P.R. China, Guangdong Second People's Hospital, Guangzhou, Guangdong 510317, P.R. China, Institute of Clinical Medicine, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510630, P.R. China
Published online on: September 26, 2019 https://doi.org/10.3892/mmr.2019.10712
Pages: 4499-4506
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aberrant expression of sialyltransferase has a role in cell differentiation, neoplastic transformation and the progression of various types of cancer. Our previous studies have shown that high expression of β‑galactoside‑α2,3‑sialyltransferase III (ST3Gal3) in the metastatic ovarian cancer cell line HO8910PM attenuated cisplatin‑induced apoptosis. The present study demonstrated that paclitaxel‑induced chemoresistance in ovarian cancer cells upregulated the expression of ST3Gal3 and reduced the activity of caspase‑8/3. The results of the present study revealed that the endogenous levels of ST3Gal3 mRNA and protein were significantly higher in HO8910PM cells compared with SKOV3 cells. A higher expression of ST3Gal3 was correlated with an increased resistance to paclitaxel, while the downregulation of ST3Gal3 resulted in paclitaxel‑induced apoptosis. Paclitaxel upregulated ST3Gal3 expression at the mRNA and protein levels in HO8910PM cells, but not in SKOV3 cells. Silencing of ST3Gal3 by small interfering RNA reversed these effects and increased the protein levels of caspase‑8/3, which may contribute to paclitaxel‑induced apoptosis. The results of the present study suggested that ST3Gal3 was a target for paclitaxel‑related resistance during ovarian cancer chemotherapy.

View Figures

View References

1	Prat J; FIGO Committee on Gynecologic Oncology, : Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer. 121:3452–3454. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Rossing MA, Wicklund KG, Cushing-Haugen KL and Weiss NS: Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst. 102:222–229. 2010. View Article : Google Scholar : PubMed/NCBI
4	Zheng X, Chen S, Li L, Liu X, Liu X, Dai S, Zhang P, Lu H, Lin Z, Yu Y and Li G: Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125. J Gynecol Obstet Hum Reprod. 47:227–230. 2018. View Article : Google Scholar : PubMed/NCBI
5	Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, et al: A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol. 149:585–591. 2018. View Article : Google Scholar : PubMed/NCBI
6	Ferreira JA, Magalhães A, Gomes J, Peixoto A, Gaiteiro C, Fernandes E, Santos LL and Reis CA: Protein glycosylation in gastric and colorectal cancers: Toward cancer detection and targeted therapeutics. Cancer Lett. 387:32–45. 2017. View Article : Google Scholar : PubMed/NCBI
7	Dall'Olio F, Malagolini N, Trinchera M and Chiricolo M: Sialosignaling: Sialyltransferases as engines of self-fueling loops in cancer progression. Biochim Biophys Acta. 1840:2752–2764. 2014. View Article : Google Scholar : PubMed/NCBI
8	Biskup K, Braicu EI, Sehouli J, Tauber R and Blanchard V: The ascites N-glycome of epithelial ovarian cancer patients. J Proteomics. 157:33–39. 2017. View Article : Google Scholar : PubMed/NCBI
9	Rodrigues JG, Balmaña M, Macedo JA, Poças J, Fernandes Â, de-Freitas-Junior JCM, Pinho SS, Gomes J, Magalhães A, Gomes C, et al: Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cell Immunol. 333:46–57. 2018. View Article : Google Scholar : PubMed/NCBI
10	Kuzmanov U, Musrap N, Kosanam H, Smith CR, Batruch I, Dimitromanolakis A and Diamandis EP: Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clin Chem Lab Med. 51:1467–1476. 2013. View Article : Google Scholar : PubMed/NCBI
11	Alley WR Jr, Vasseur JA, Goetz JA, Svoboda M, Mann BF, Matei DE, Menning N, Hussein A, Mechref Y and Novotny MV: N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res. 11:2282–2300. 2012. View Article : Google Scholar : PubMed/NCBI
12	Shetty V, Nickens Z, Shah P, Sinnathamby G, Semmes OJ and Philip R: Investigation of sialylation aberration in N-linked glycopeptides by lectin and tandem labeling (LTL) quantitative proteomics. Anal Chem. 82:9201–9210. 2010. View Article : Google Scholar : PubMed/NCBI
13	Shetty V, Hafner J, Shah P, Nickens Z and Philip R: Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin Proteomics. 9:102012. View Article : Google Scholar : PubMed/NCBI
14	Mikami M, Tanabe K, Matsuo K, Miyazaki Y, Miyazawa M, Hayashi M, Asai S, Ikeda M, Shida M, Hirasawa T, et al: Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma. Gynecol Oncol. 139:520–528. 2015. View Article : Google Scholar : PubMed/NCBI
15	Matsuo K, Tanabe K, Ikeda M, Shibata T, Kajiwara H, Miyazawa M, Miyazawa M, Hayashi M, Shida M, Hirasawa T, et al: Fully sialylated alpha-chain of complement 4-binding protein (A2160): A novel prognostic marker for epithelial ovarian carcinoma. Arch Gynecol Obstet. 297:749–756. 2018. View Article : Google Scholar : PubMed/NCBI
16	Wen KC, Sung PL, Hsieh SL, Chou YT, Lee OK, Wu CW and Wang PH: α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells. Oncotarget. 8:29013–2902. 2017. View Article : Google Scholar : PubMed/NCBI
17	Christie DR, Shaikh FM, Lucas JA IV, Lucas JA III and Bellis SL: ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res. 1:32008. View Article : Google Scholar : PubMed/NCBI
18	Mikuła-Pietrasik J, Uruski P, Szubert S, Szpurek D, Sajdak S, Tykarski A and Książek K: Malignant ascites determine the transmesothelial invasion of ovarian cancer cells. Int J Biochem Cell Biol. 92:6–13. 2017. View Article : Google Scholar : PubMed/NCBI
19	Szender JB, Emmons T, Belliotti S, Dickson D, Khan A, Morrell K, Khan AN, Singel KL, Mayor PC, Moysich KB, et al: Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol. 146:491–497. 2017. View Article : Google Scholar : PubMed/NCBI
20	Orr B and Edwards RP: Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 32:943–964. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zeng J, Huang H, Shan Y, Li Y, Jin Y and Pan L: The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery. J Cancer. 8:3410–3415. 2017. View Article : Google Scholar : PubMed/NCBI
22	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
23	Webber K and Friedlander M: Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Pract Res Clin Obstet Gynaecol. 41:126–138. 2017. View Article : Google Scholar : PubMed/NCBI
24	Liu N, Mei L, Fan X, Tang C, Ji X, Hu X, Shi W, Qian Y, Hussain M, Wu J, et al: Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett. 378:38–50. 2016. View Article : Google Scholar : PubMed/NCBI
25	Maji S, Panda S, Samal SK, Shriwas O, Rath R, Pellecchia M, Emdad L, Das SK, Fisher PB and Dash R: Chapter three-Bcl-2 antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res. 137:37–75. 2018. View Article : Google Scholar : PubMed/NCBI
26	Ween MP, Armstrong MA, Oehler MK and Ricciardelli C: The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol. 96:220–256. 2015. View Article : Google Scholar : PubMed/NCBI
27	Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al: Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 317:2402–2416. 2017. View Article : Google Scholar : PubMed/NCBI
28	Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M and Menkiszak J: Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? PLoS One. 13:e01942702018. View Article : Google Scholar : PubMed/NCBI
29	Britain CM, Holdbrooks AT, Anderson JC, Willey CD and Bellis SL: Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death. J Ovarian Res. 11:122018. View Article : Google Scholar : PubMed/NCBI
30	Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN and Bellis SL: ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res. 6:252013. View Article : Google Scholar : PubMed/NCBI
31	Wang X, Zhang Y, Lin H, Liu Y, Tan Y, Lin J, Gao F and Lin S: Alpha2,3-sialyltransferase III knockdown sensitized ovarian cancer cells to cisplatin-induced apoptosis. Biochem Biophys Res Commun. 482:758–763. 2017. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Geisler C and Jarvis DL: Effective glycoanalysis with Maackia amurensis lectins requires a clear understanding of their binding specificities. Glycobiology. 21:988–993. 2011. View Article : Google Scholar : PubMed/NCBI
34	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
35	Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of Taxol resistance related to microtubules. Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
36	Bennun SV, Hizal DB, Heffner K, Can O, Zhang H and Betenbaugh MJ: Systems glycobiology: Integrating glycogenomics, glycoproteomics, glycomics, and other ‘omics data sets to characterize cellular glycosylation processes. J Mol Biol. 428:3337–3352. 2016. View Article : Google Scholar : PubMed/NCBI
37	Wu J, Xie X, Nie S, Buckanovich RJ and Lubman DM: Altered expression of sialylated glycoproteins in ovarian cancer sera using lectin-based ELISA assay and quantitative glycoproteomics analysis. J Proteome Res. 12:3342–3352. 2013. View Article : Google Scholar : PubMed/NCBI
38	Cheng WK and Oon CE: How glycosylation aids tumor angiogenesis: An updated review. Biomed Pharmacother. 103:1246–1252. 2018. View Article : Google Scholar : PubMed/NCBI
39	Zhang X, Pan C, Zhou L, Cai Z, Zhao S and Yu D: Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells. BMC Cancer. 16:9492016. View Article : Google Scholar : PubMed/NCBI
40	Goldberg JM, Piver MS, Hempling RE and Recio FO: Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol. 63:312–317. 1996. View Article : Google Scholar : PubMed/NCBI
41	du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, et al: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Semin Oncol. 24 (5 Suppl 15):S15-44–S15-52. 1997.